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1. Introduction
Advanced stage non-small cell lung cancer (AS-NSCLC) is generally
treated with concurrent chemoradiotherapy using a radiation dose of
60–66 Gray (Gy) in 30–33 fractions over six-seven weeks [1]. Intensity-
modulated radiation therapy (IMRT) and volumetric modulated arc
therapy (VMAT) are widely used treatment techniques [2].
Radiation treatment plans are becoming increasingly complex [3]
and manual optimization of treatment plans is time-consuming and the
quality of the plan is operator dependent [4]. The increasing complexity
of treatment plans complicates the optimization procedure and thereby
augments the rate of inconsistency between manually derived treat-
ment plans [3,5]. Several trial-and-error optimization processes are
usually required to achieve clinically acceptable plans. More manual
actions could influence consistency and plan quality of the manual
treatment plans [3,4]. The experience of the planner has a large impact
on plan quality and dissemination of best practices could help improve
these variations [6].
Aforementioned drawbacks of manual treatment planning might be
overcome by automating treatment planning. Most treatment planning
systems currently have integrated an automated treatment planning
solution. In addition, there are also in-house developed automated
treatment planning systems [7]. Automated treatment planning
methods are aimed to reduce the inter-planner variability and the
planning time during the optimization process and to improve plan
quality. Different sites investigated were already investigated such as
head and neck (H&N) [4,5,8,9], prostate [10] and oesophagus [11].
Automated treatment plans for AS-NSCLC radiation therapy are not
much represented yet. The location of a tumor in the lung varies more
than the location of a tumor in the H&N area or the prostate. This
variability may cause a difference in the result of automated treatment
planning techniques. Della Gala et al. [7] investigated different radia-
tion techniques for AS-NSCLC by comparing originally manually
planned IMRT treatment plans versus automated VMAT treatment plans
with their in-house developed treatment planning system Erasmus-
iCycle. In this study we have investigated, if automated treatment
planning is able to create treatment plans with consistent quality using
a single optimization preset including beam set-up, dose prescription,
objectives and priorities for organs at risk (OARs), and planning target
volumes (PTVs) for AS-NSCLC. A comparison is presented between
automated and manually generated VMAT treatment plans for AS-
NSCLC.
2. Materials and methods
2.1. Study design and inclusion criteria
We performed a quantitative retrospective planning study to de-
velop an automated VMAT treatment planning procedure for AS-
NSCLC. The treatment plans of twenty-five consecutive AS-NSCLC pa-
tients originally planned in the period 2016 – 2017 were re-planned
using the Auto-Planning module in Pinnacle 9.10. Three cases were
excluded when either a second dose level was specified to part of the
PTV or when adjustments to the protocol were done. All remaining
twenty-two plans were designed to deliver 66 Gy in daily fractions of
2 Gy to the primary tumor and the lymph node metastases.
Male and female patients were included regardless of age, locali-
sation of the primary tumor or tumor size. The median age of twenty-
two patients (six female; sixteen male) was 63.5 years (range
53–83 years). The primary tumor was located in the left lung in seven
patients, and in the right lung in fifteen patients. The median PTV was
326 cm3 (range 103–940 cm3).
The PTV consist of the CTV+10mm margin, whereby the CTV was
formed by tumor GTV+5mm margin and lymph node GTV with no
margin. The internal target volume (ITV) was used as the motion
management technique for the treatment plans. The OARs, which were
eligible for contouring, were oesophagus, lungs, myelum, heart, plexus
brachialis, sternum and ribs.
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2.2. Planning technique
The clinical treatment plans were planned with the clinical version
of Pinnacle 9.10 (Philips Radiation Oncology Systems, Fitchburg, WI,
USA) using the VMAT technique. The Auto-Planning module within the
clinical version of Pinnacle 9.10 was used to plan the automated
treatment plans. Treatment plans were calculated with a dose grid of
3mm. The clinical plans were made using a model for an Elekta
Synergy linear accelerator (Elekta AB, Stockholm, Sweden) with a
Agility™ multileaf collimator for 10megavolt (MV) photons. The
number of beams were doubled for the automated treatment plans,
giving these plans more space to fulfil the dose criteria.
Clinical plans were made using one partial VMAT arc. However, one
partial VMAT arc did not appear to be sufficient for automated plans to
make clinical acceptable plans for all cases. Therefore, the partial
VMAT arc of the manual plan was copied and therefore two VMAT arcs
were used for the automated plans.
The planning templates were tested through trial-and-error to in-
vestigate the possible settings for the automated treatment plans. The
settings were first tested on four treatment plans. After this, the settings
were evaluated on the remaining treatment plans. High priority is not
used in this setting, because this setting appears to have a strong impact
on the dose distribution of the PTV.
If the tumor was located left ventral or right ventral, the beam an-
gles for the manual and automated plans were the same. If the tumor
was located left dorsal or right dorsal, the beam angles differ from each
other. The manual angles for left dorsal were 216–20° counter clock-
wise (CCW) and for right dorsal the angles were 20−140° CCW. For the
automated plans the beam angles were changed a little, because we did
not want the beam angle go through the 180°, because this was physical
not possible. The template setting for the automated treatment plan
were described in Table S1 see Supplementary material.
The template setting was developed to meet the prescription and
dose criteria of the automated treatment plan for AS-NSCLC (see
Table 1).
In clinical practice the plan quality always improved after per-
forming a warm re-start, i.e. calculate the treatment plan without re-
setting the previous optimization results. After the warm re-start
scorecards were used to check if the planning goals were met. If a goal
was not met, another warm re-start is performed after manual adap-
tation of an objective.
2.3. Data collection and analysis
The plan quality between the original manual optimized and auto-
mated VMAT treatment plans were compared by means of conformity
index (CI) and homogeneity index (HI). CI assesses the dose conformity
of a region of interest (ROI), and HI assesses the dose homogeneity of a
ROI [4,12,13].
The CI was calculated by the formula of Van ‘t Riet [14], which is
the most clean way of describing CI, because it simultaneously takes
into account irradiation of the target volume and irradiation of healthy
tissues [15]:
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V95%PTV =volume of the PTV receiving 95% of the prescribed dose.
VPTV =volume of the PTV.
V95% =volume of the 95% isodose.
The optimal value of the CI is 1 [12]. The lower the CI, the lower the
conformity of the PTV in a treatment plan [12].
The HI was calculated by the formula of the International
Commission on Radiation Units and Measurements (ICRU) [13]:
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D PTV2% =2% of the volume of the PTV receives that dose or more
(near maximum dose).
D PTV98% =98% of the volume of the PTV receives that dose or more
(near minimum dose).
D PTV50% =50% of the PTV received dose (median dose).
The ideal value for HI is zero and it increases as homogeneity de-
creases [13,16].
Treatment plans were also compared using dose-volume histograms
(DVHs) and monitor units (MUs) [4,17]. Distributions of the CIs, HIs,
DVHs and MUs were visually assessed using histograms. In case of a
skewed data, the median and interquartile range were used to describe
the data. Further statistical analysis was performed with the Wilcoxon
signed rank test. Differences between plans were considered statisti-
cally significant if p < 0.05. An in-house developed DVH-tool, using
Matlab version R2016a (The MathWorks Inc., Natick, MA, United
States) software was used for comparing dose values of PTVs and OARs
for all plans.
Plan QA was performed on a Delta4 phantom (Scandidos, Uppsala,
Sweden) [18]. A plan is accepted if more than 95% of the measured
point within the 40% isodose surface (related to the prescribed dose)
fulfilled γ-criteria of 3% (related to measured maximum dose) or 3mm
distance.
2.4. Evaluation of planning time
To evaluate the cost effectiveness of the automated planning pro-
cedure we analysed hands-on time for both the automated and the
manual planning procedure. The hands-on-time was estimated for the
time a planner is actively working on the treatment plan.
3. Results
For eleven of the twenty-two automated plans, the plans were ready
after automated planning and a seperate warm optimization re-start
were done. For the remaining eleven plans, another warm re-start was
performed after manual adaptation of an objective weight or value for
Table 1
Prescription for stage III AS-NSCLC.
Prescription 66 Gy in 33 fractions (33x2Gy)
ROI Dose
PTV V95% ≥99%
PTV Dmean: 66 Gy (maximum 67,5 Gy)
Hot spots in PTV 107%≤ “hot spot” ≤110%
“hot spot” ≤2 cm3
Oesophagus in PTV Dmax: 66 Gy (100%)
Dmin: 62,7 Gy (95%)
Oesopahgus+ 2mm Dmax: V35 Gy < 50%
Dmax: V50 Gy < 40%
Dmax: V65 Gy < 35%
Dmax: V70 Gy < 20%
Both lungs (lungs – GTV) Dmax: V20 < 30%
Both lungs (lungs – GTV) Dmean: < 19 Gy
Spinal cord Dmax: 50 Gy
Spinal cord+ 3mm Dmax: 50 Gy
Heart Dmax: V25 Gy < 10%
Dmax: V30 Gy < 46%
Dmax: V50 Gy < 40%
Heart Dmean: < 26 Gy
Plexus brachialis Dmax: 66 Gy
Sternum Dmax: 66 Gy
Ribs Dmax: 66 Gy
Gy: Gray, ROI: Region Of Interest, V: Volume, Dmean: Mean Dose, Dmax:
Maximum Dose, Dmin: Minimum Dose, GTV: Gross Tumor Volume.
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some OARs before the plan was clinical acceptable. The treatment plans
obtained by automated planning were superior compared to the
manually derived plans, an example is given in Fig. 1. The spider-web
diagram of Fig. 1 shows visually the reduction in dose to the OARs by
the automated planning procedure.
3.1. PTV
As shown in Table 2, there was a significant improvement in HI for
the PTV from 0.09 to 0.07 favouring the automated plans.
No significant difference was seen in PTV V95% coverage, PTV
Fig. 1. A subset of the plan quality metrics for PTV and dose metrics comparison for OARs. Upper panels show an example of the transversal dose distribution for the
original clinical (upper left panel) and automated plan (upper right panel). In the lower panels, the plan quality is evaluated for all plans comparing the manual (light
blue) with the automated plans (dark blue). The plan quality criteria for PTV are plotted and scaled (if necessary) for visualisation: V95% (divided by 100), HI
(multiplied with factor 10) and CI. In the lower right panel, the dose metrics to the OARs are shown. PTV: Planning Target Volume, OAR: Organ At Risk, V: Volume,
HI: Homogeneity Index, CI: Conformity Index, Oes: Oesophagus, GTV: Gross Tumor Volume, Dmean: Mean Dose, Dmax: Maximum dose. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2
Dose metrics results for PTV and OARs.
Organs Parameters Median
Manual
Median
AP
IQR
Manual
IQR
AP
P-value
PTV V95Gy (%) 99.0 99.1 0.6 0.5 0.5
PTV Dmean (Gy) 66.3 66.3 0.5 0.3 0.4
PTV CI 0.8 0.8 0.1 0.0 0.4
PTV* HI (x10) 0.9 0.7 0.2 0.1 0.001
Oesophagus+ 2mm Dmean (Gy) 58.0 55.1 7.8 5.5 <0.001
Oesophagus+ 2mm V35Gy (%) 26.2 23.2 14.0 19.1 <0.001
Oesophagus+ 2mm V50Gy (%) 14.5 12.9 15.0 15.7 <0.001
Oesophagus+ 2mm V65Gy (%) 2.6 4.0 7.8 8.2 0.2
Oesophagus+ 2mm V70Gy (%) 0.0 0.0 – 0.0 0.2
Lungs – GTV V20Gy (%) 26.0 25.6 10.3 9.8 0.001
Lungs – GTV Dmean (Gy) 15.8 15.7 5.9 5.9 0.002
Spinal cord Dmax (Gy) 44.8 39.4 5.5 14.8 <0.001
Spinal cord+ 3mm Dmax (Gy) 47.4 45.7 7.7 16.3 0.002
Heart Dmean (Gy) 8.2 4.8 9.3 7.3 <0.001
Heart V25Gy (%) 9.2 3.2 17.1 12.5 0.001
Heart V30Gy (%) 7.2 2.6 14.5 10.4 <0.001
Heart V50Gy (%) 2.9 1.0 6.2 3.4 <0.001
Plexus brachialis Dmax (Gy) 65.9 65.4 – – 0.6
Monitor Units MUs (#) 350 460 90.2 120.7 <0.001
P < 0.05 is statistical significant.
AP: Auto-Planning, IQR: Interquartile Range, PTV: Planning Target Volume, V: Volume, Dmean: Mean Dose, Gy: Gray, CI: Conformity Index, HI: Homogeneity Index,
* HI values are multiplied with factor 10 in this Table, GTV: Gross Tumor Volume, Dmax: Maximum Dose, MUs: Monitor Units.
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mean dose (Dmean) and conformity between the automated treatment
plans and the manually derived treatment plans.
Twenty automated plans showed a PTV V95% coverage of 99% or
higher, whereas only eleven manual plans had a PTV V95% coverage of
99% or higher. Of the two automated plans with a PTV V95% coverage
lower than 99% (98% and 97% respectively), the corresponding
manual PTV V95% coverage was also lower than 99%. A large part of
the PTV of these two patients was in the vicinity of the oesophagus, and
a V95% coverage of 99% or more have resulted in a large number of
hotspots. Given these results, these automated treatment plans were
clinically acceptable plans and approved by a clinical physician, phy-
sicist and an experienced treatment planner.
3.2. OARs and dose metrics
With automated planning a significant reduction of dose delivered
to OARs (Table 1) was found favoring the automated plans (Table 2).
This was the case for several parameters: ‘oesophagus+ 2mm’
(Dmean, V35Gy and V50Gy), ‘lungs – GTV’ (V20Gy and Dmean), ‘spinal
cord’ (Dmax), ‘spinal cord+3mm’ (Dmax), and ‘heart’ (Dmean,
V25Gy, V35Gy and V50Gy).
The Dmean, V35Gy and the V50Gy of the volume ‘oeso-
phagus+ 2mm’ were significantly reduced with 2.9 Gy, 3% and 2%,
respectively. However, the V65Gy of the volume ‘oesophagus+ 2mm’
was increased with 1.4% in the automated plans, but this was not a
significant difference.
The ‘lungs – GTV’ volume received a reduced dose in the automated
plans. However, the significant differences for V20Gy and Dmean were
0.4% and 0.1 Gy, respectively.
The maximum doses in the spinal cord and in the spinal
cord+ 3mm were significant reduced in the automated treatment
plans than in the manual treatment plans. The differences between the
plans were 5.4 Gy and 1.7 Gy respectively in favour of the automated
plans.
The heart also received a reduced dose in the automated treatment
plans than in the manual treatment plans. Statistical significant differ-
ences of the heart Dmean, V25Gy, V30Gy and V50Gy were found. The
differences were 3.4 Gy, 6%, 5% and 2%, respectively.
3.3. MUs
The number of MUs in the automated treatment plans was sig-
nificantly higher than the manual treatment plans. This was the case in
21 of the 22 automated treatment plans. The difference was 110 MUs.
3.4. Planning time
The total estimated planning time for both the automated and the
manual treatment plans was four hours. However, the estimated hands-
on-time of the manual treatment plans was about two hours, whereas
the estimated hands-on-time of the automated treatment plans was only
about thirty minutes.
4. Discussion
The aim of this study was to develop an automated VMAT treatment
planning for AS-NSCLC patients and evaluate the plan quality between
the original manual optimized and automated VMAT treatment plans,
for daily clinical practice. It was reassuring that no significant differ-
ences between the PTV V95% and the PTV Dmean were found. This
could be explained by the fact that these criteria are determined be-
forehand. The template was adjusted to meet these criteria. The dose to
the PTV V95% was similar in the automated and manual treatment
plans, as well as PTV Dmean and the CI. Automated and manual
treatment plans performed equally with respect to these criteria. The
automated treatment plans achieved a significant improvement in
homogeneity of the PTV and dose reduction for OARs, whereby the
quality of the treatment plans were comparable with the clinical plans.
We showed that a single template setup for automated treatment
planning lead to plans of consistent and high quality, fulfilling the
clinical dose criteria for the PTV with maximal sparing of the OARs for
patients with AS-NSCLC. The hands-on planning time was reduced from
two hours to thirty minutes. Besides its efficiency and consistency, the
automated plans gave significantly lower doses to the surrounding or-
gans at risk: ‘oesophagus+ 2mm’ (V35Gy and V50Gy), ‘lungs – GTV’
(V20Gy and Dmean), ‘spinal cord’ (Dmax), ‘spinal cord+ 3mm’
(Dmax), and ‘heart’ (Dmean, V25Gy, V35Gy and V50Gy). This dose
reduction could result in a significant decrease in acute side effects for
instance for the oesophagus and late toxicity for the heart. Although a
reduction of an already low dose of the spinal cord has no direct ad-
vantage for the patient, this indicates that in case of closer vicinity of
the PTV to the spinal cord automated planning may allow a high dose to
the PTV while maintaining an low complication probability of the
spinal cord, thereby enhancing the therapeutic window.
Automated treatment planning gave a significant reduction of dose
delivered to several parameters of various OARs. So even though our
manual treatment plans were made by experienced treatment planners,
the automated planning technique was able to achieve better sparing of
the OARs. Again this has also been reported before: for AS-NSCLC by
Della Gala et al. [8] and for head and neck tumors by Hazell et al. [5],
Hansen et al. [8], Krayenbuehl et al. [4] and Gintz et al. [19]. However,
in our study, the V65Gy of the volume ‘oesophagus+ 2mm’ was
slightly higher in the automated plans than in the manual treatment
plans. This was due to the vicinity of the PTV to the oesophagus in
combination with increased homogeneity of PTV coverage in the au-
tomated treatment plans. The automated plans were clinically accep-
table for this parameter.
This study was most comparable with the article of Della Gala et al.
[7] who also examined treatment planning for AS-NSCLC. The results of
the HI, ‘lungs – GTV’ V20Gy and Dmean and heart Dmean were com-
pared. These dose metrics were all improved with the automated
treatment planning. The aforementioned dose metrics of the manual
and automated plans are in this study superior to the results of the dose
metrics of the article of Della Gala et al. [7]. Most likely, because we
made manual VMAT plans instead of manual IMRT plans and probably
the different use of arcs. The hands-on time was also seen to be de-
creased in both articles.
Implementation of the automated planning within the clinic is not
straightforward and needs to be carefully introduced into the clinic by
an expert team who have the skills and experience to understand how
automated planning can deliver high quality plans. Thorough testing
needs to be done to ensure that the generated automated plans are as
least as good as the manually clinical plans in all cases. Therefore, a
representative subset of clinical cases needs to be tested and compared
with the originally manual plans before introducing automated plan-
ning into the clinic.
Generally, a single template is used for all patients, which may limit
finding the optimal plan for all patients. However, it would be better to
make a patient-specific planning template. There are several alternative
options for personalization of planning goals, including Knowledge-
Based solutions like Rapidplan available in Eclipse (Varian Medical
Systems, Palo Alto, USA) and Multicriteria Optimization (MCO) avail-
able in Raystation (Raysearch Laboratories, Stockholm, Sweden) and
Erasmus-iCycle. Pinnacle introduced PlanIQ Feasibility, which provides
a patient-specific estimation of the best-case scenario dose distribution,
we did not yet use this.
We developed an overlap volume histogram (OVH)-based method
for automated prostate plans to check the plan quality of the automated
plans [20]. This tool could also be used to set a patient-specific planning
template before starting the treatment process. This tool was not used in
this study. Currently we are investigating the implementation of this
tool for the automated lung plans obtained in this study. Although the
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automated planning should be robust, a plan quality control tool is
necessary to guarantee that for each patient the generated plan fulfills
clinical criteria for the patient-specific anatomy. For Pinnacle typically
a scorecard which contains clinical goals is used to evaluate the plan
quality. However, these scorecards are based on general protocols and
do not take into account the possible patient specific endpoints. Cur-
rently, different machine learning techniques [21,22] are developed to
predict the 3D dose distribution and integrated in the planning process.
Also our in-house developed plan quality control tool can be used the
further improve the plan quality.
Furthermore, the beam configuration like for example collimator
rotation [23] may influence the plan quality. In this study we used a
collimator rotation of 20° and did not investigate how other values
could influence the plan quality.
The number of MU in the automated treatment plans was sig-
nificantly higher than in the manual treatment plans. This was caused
by the use of two VMAT arcs instead of one arc and by increased
multileaf collimator (MLC) modulation. Considering the benefits of
automated treatment planning, we found the increase in MU accep-
table. In head and neck tumors, Hansen et al. [8] found an average
increase of 75MU per treatment plan for automated treatment plans in
comparison with manual VMAT treatment plans, which was in the same
order of magnitude of our study.
Manual and automated plans differ in (partial) arcs arrangement:
manual plans exploit one arc, while automated plans used two arc ar-
rangements. Despite the fact that a double arc arrangement increases
the robustness of the automated planning technique, it might also im-
prove the plans itself. We were forced to choose different numbers of
beams, because one partial VMAT arc was not sufficient for the auto-
matic plans to meet the criteria. To keep the other settings as much the
same as possible, we decided to double the beam setup for the auto-
mated treatment plans.
Moreover, the four treatment plans from the trial-and-error tem-
plate were included in the results. These four treatment plans were
chosen by a second person and not the investigator. If the template was
only focused on these four plans, the template settings would give no
good results for the other plans, which was not the case in this study
population. The sternum and the ribs were not classified as OARs in any
plan by the radiation oncologist. These OARs had not been examined in
the template. The brachial plexus is included in three of the twenty-two
radiation plans. If the brachial plexus was present in a treatment plan,
manual optimization was used, so that the plan clinically met the cri-
teria. In this study no conclusions could be drawn about these critical
organs.
The process to generate automated plans completely automatic only
succeeded for half of the patient plans. This was due to the fact that
only a single template setting was used for all patient plans. However,
the other plans could been made clinical acceptable very easy by doing
a warm restart and adapting the settings based on the scorecard results.
Therefore, we concluded that automated plans were less dependent on
the experience of the planner and on the planning process in general.
Although there is no limit in making more template settings, our ap-
proach was to use one single template for all patient plans. In the future
individual adaption of the template could lead to an more in-
dividualized automated plan approach.
Our findings indicate, that the plan quality of the automated
treatment plans was better than the clinically manually optimized
treatment plans for patients with AS-NSCLC and the hands-on-planning
time was reduced from two hours to thirty minutes. Our department has
implemented automated treatment planning into the standard clinical
practice for these patients.
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